314 related articles for article (PubMed ID: 31982075)
1. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC;
Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
[TBL] [Abstract][Full Text] [Related]
4. Should We Stop Treating Patients With Eplerenone for Chronic CSCR? Commentary on the VICI Trial.
Daugirdas SP; Bheemidi AR; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):308-310. PubMed ID: 34185584
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
[TBL] [Abstract][Full Text] [Related]
7. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
[TBL] [Abstract][Full Text] [Related]
8. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study.
Rajesh B; Agrawal H; Peguda HK; Chhablani J
Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.
Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP
Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056
[TBL] [Abstract][Full Text] [Related]
11. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
Venkatesh R; Pereira A; Jain K; Yadav NK
BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
[No Abstract] [Full Text] [Related]
13. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
[TBL] [Abstract][Full Text] [Related]
15. [Eplerenone treatment in chronic central serous chorioretinopathy].
Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
Raman SV; Hor KN; Mazur W; Halnon NJ; Kissel JT; He X; Tran T; Smart S; McCarthy B; Taylor MD; Jefferies JL; Rafael-Fortney JA; Lowe J; Roble SL; Cripe LH
Lancet Neurol; 2015 Feb; 14(2):153-61. PubMed ID: 25554404
[TBL] [Abstract][Full Text] [Related]
18. Eplerenone for treatment of chronic central serous chorioretinopathy.
Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD
Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564
[TBL] [Abstract][Full Text] [Related]
19. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]